Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Julien, B. Articles by Shah, S. Search for Related Content PubMed PubMed Citation Articles by Julien, B. Articles by Shah, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2002, p. 2772-2778, Vol. 46, No. 9
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.9.2772-2778.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Heterologous Expression of Epothilone Biosynthetic Genes in Myxococcus xanthus

Bryan Julien^* and Sanjay Shah

Kosan Biosciences, Inc., Hayward, California 94545

Received 15 January 2002/ Returned for modification 22 April 2002/ Accepted 1 June 2002

Top Abstract Introduction Materials and Methods Results Discussion References

 
Epothilones are potential anticancer drugs that stabilize microtubules in a manner similar to paclitaxel (Taxol). Epothilones are produced from the myxobacterium Sorangium cellulosum, which has a 16-h doubling time and produces only milligram-per-liter amounts of epothilone A and epothilone B. Furthermore, genetic manipulation of S. cellulosum is difficult. To produce epothilones in a more genetically amenable and rapidly growing host, we chose the closely related and best-characterized myxobacteria Myxococcus xanthus. We inserted 65.4 kb of S. cellulosum DNA that encompassed the entire epothilone gene cluster into the chromosome of M. xanthus by a series of homologous recombination events. The resulting strain produced epothilones A and B. Construction of a strain that contained a mutation in epoK, the P450 epoxidase, resulted in production of epothilones C and D.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Epothilones are potent cytotoxic macrocyclic lactones that show promise as anticancer drugs (21, 22, 26). The mechanism of action is similar to the anticancer drug paclitaxel (Taxol); both bind and stabilize microtubules, which leads to cell death (3). Epothilones have superior features relative to paclitaxel. First, epothilones are more water soluble. This may enable a formulation without the use of the solubilizing agent cremophor, currently used in formulations of paclitaxel. Cremophor, on its own, can affect cardiac function and cause severe hypersensitivity (25). Second, epothilones are effective against tumors resistant to paclitaxel (3, 31). These advantages make epothilones likely successors to paclitaxel.

The need for sufficient material is a major obstacle to the development of epothilones as marketable drugs. The total synthesis of epothilone A and epothilone B has been accomplished (2, 32). However, the number of steps required for synthesis of these molecules precludes this as an economical method of production. Fermentation methods thus remain the favored route of production.

Epothilones are produced from the gram-negative myxobacterium Sorangium cellulosum (8). The reported yields of epothilones from S. cellulosum strain So ce90 are approximately 20 mg of epothilone A per liter and 10 mg of epothilone B per liter (8). A disadvantage of S. cellulosum is the relatively long doubling time, which is approximately 16 h and is the longest of all myxobacteria. Furthermore, S. cellulosum is difficult to engineer, due to the low efficiency of introducing DNA into the bacterium (11) and the limited number of molecular tools and markers that have been developed.

Recently, the epothilone biosynthetic gene cluster was sequenced, and the genes were introduced into Streptomyces coelicolor, a common host used for production of a variety of polyketides from actinomycetes (33). The heterologous strain produced small quantities of epothilones; production of epothilones in S. coelicolor may have a cytotoxic effect (L. Tang et al., unpublished data). Thus, an alternative heterologous host is desired.

We speculated that a superior expression host for epothilones might be another myxobacterium and chose Myxococcus xanthus for several reasons. First, M. xanthus is the best-characterized myxobacterium and is readily amenable to engineering (35). Second, M. xanthus has a significantly shorter doubling time than S. cellulosum (5 versus 16 h), which would in itself enhance volumetric productivity. Third, expression of the epothilone genes in M. xanthus may not require the engineering of new promoters, because M. xanthus and S. cellulosum are closely related organisms.

The epothilones are polyketides that are synthesized by a type I polyketide synthase (Fig. 1). These enzymes are large multifunctional complexes organized in a modular fashion and catalyze the successive condensation of carboxylic acid residues from their coenzyme A (CoA) esters, typically malonyl-CoA and methylmalonyl-CoA (10). Polyketide synthase enzymes are synthesized as an apo form and are converted to the holo form by the addition of a phosphopantetheinyl (P-pant) moiety to a serine residue of the acyl or peptidyl carrier protein (ACP or PCP) domains by an enzyme called P-pant transferase (18). Thus, a heterologous host must synthesize malonyl-CoA and methylmalonyl-CoA as well as harbor a P-pant transferase.

View larger version (19K): [in this window] [in a new window]

FIG. 1. Genetic map of the epothilone biosynthetic gene cluster. The boxes represent genes, and the modules encoded by each are designated below. The long arrow represents the direction of transcription.

Before initiating this work, it was unknown whether M. xanthus contains a P-pant transferase or methylmalonyl-CoA. It is known that strains of M. xanthus produce the polyketide myxovirescins, also known as TA. Thus, it is likely to contain a P-pant transferase, but whether it would function on the ACP and PCP domains of the epothilone polyketide synthase remained to be determined. Although myxovirescins contains methyl groups extending from the ring, they are all derived from S-adenosylmethionine and not from the utilization of methylmalonyl-CoA. Thus, evidence for the production of methylmalonyl-CoA cannot be deduced from the polyketides that are made naturally from this host. Work studying the developmental life cycle of M. xanthus has revealed the presence of the genes for propionyl-CoA carboxylase (16, 17), an enzyme used to synthesize methyl malonyl-CoA. Thus, M. xanthus is likely to possess required components to synthesize epothilone.

Because of the advantages of using M. xanthus as a host for production of epothilone, we introduced the epothilone genes from S. cellulosum into the chromosome of M. xanthus. We demonstrate that the engineered strain produces epothilones. We also constructed mutations in epoK, the CYP450, which is responsible for the formation of the epoxide at C-12-C-13. This strain produces epothilone C and epothilone D.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Bacterial strains. Escherichia coli strains XL1-Blue and DH10B were used for transformations. M. xanthus strain DZ1 was the recipient for the epothilone genes (36). It is streptomycin resistant and is a nonmotile strain that is unable to form fruiting bodies

Media and growth conditions. E. coli with plasmids were grown in Luria-Bertani medium containing 0.5% NaCl at 37°C supplemented with ampicillin (50 µg/ml), kanamycin (50 µg/ml), or tetracycline (15 µg/ml).

DZ1 was grown in CYE (4) at 30 or 32°C. For selection of galactose resistance in M. xanthus, cells were plated in 2.5 ml of CYE top agar and poured onto CYE plates containing 1% galactose. The following antibiotics were used for M. xanthus: kanamycin (50 µg/ml) and oxytetracycline (10 to 15 µg/ml).

To test for the production of epothilone, cells were cultured in CMM (0.5% Casitone, 0.2% MgSO₄, 10 mM morpholinepropanesulfonic acid [MOPS] [pH 7.6]) supplemented with the following amino acids (1 mg/liter): serine, glycine, and alanine. The cells were initially grown in CYE medium, and while in mid-log phase a 5% inoculum was used to inoculate a flask containing production medium. The cultures were grown at 30°C for 64 to 72 h.

XAD-16 is an absorber resin that was used in production cultures to bind the epothilones. To prepare the XAD-16, 2% was added to a fermentation flask, covered with water, and autoclaved. Afterwards, the water was removed, CMM was added, and the culture was inoculated.

Extraction of epothilones. To extract epothilones from cells and from the culture (cells and medium), an equal volume of acetone was added and shaken at room temperature for an hour. The acetone mixture was extracted twice with an equal volume of ethyl acetate, and the ethyl acetate fraction was dried and resuspended in acetonitrile.

To analyze epothilones bound to XAD-16, the culture broth was removed and the resin was washed twice with 5 volumes of MilliQ water. The epothilones were eluted with methanol and analyzed by liquid chromatography-mass spectrometry (33).

DNA methods. Standard DNA protocols were used for E. coli. The isolation of M. xanthus chromosomal DNA was done as previously described (1). Electroporation of M. xanthus was described by Kashefi and Hartzell (15)

Transposition reactions. The tetracycline resistance gene was added to the cosmids pKOS35-70.1A2 and pKOS35-79.85 (13) using the in vivo transposition reaction kit from Epicentre Technologies. The transposon used was EZ::TN<TET-1>, and the reaction was performed as recommended by the manufacturer. Resulting tetracycline-resistant colonies were screened for resistance to kanamycin. Those colonies resistant to tetracycline and sensitive to kanamycin were kept, and the DNA was digested with restriction enzymes to verify that no deletions had occurred. The tetracycline resistant versions of pKOS35-70.1A2 and pKOS35-79.85 are pKOS90-38 and pKOS90-23, respectively.

Construction of pKOS35-154 and pKOS90-22. Plasmids that contained regions of the epo genes flanked by M. xanthus DNA were constructed for homologous recombination of the epo genes into the chromosome. Plasmid pKOS35-154 was constructed in several steps. First, the ca. 3-kb BamHI-to-NdeI fragment from KG2 (35) was ligated into the BglII and NdeI sites of pSL1190 (Amersham-Pharmacia). This plasmid, pKOS55-178, contains the kanamycin resistance and galK cassette that is used for positive and negative selection in M. xanthus. Next, a 4.7-kb NotI fragment from cosmid pKOS35-79.85, containing a portion of the coding sequence for module 7, was ligated into the NotI site of pKOS55-178 to create pKOS55-183.b. Plasmid pKOS55-183.b was cleaved with MfeI, and the DNA ends were made blunt with the Klenow fragment of DNA polymerase I and ligated with a 5,088-bp SrfI fragment from pKOS35-79.85. This plasmid, pKOS90-1, contains two regions of the epo gene cluster flanking the kanamycin resistance and galK cassette. To add flanking DNA from M. xanthus to recombine the epo genes from pKOS90-1 into the chromosome, plasmid pKOS35-151 was constructed as follows. Plasmid pBJ130 (12), which carries the dev locus from M. xanthus, was cleaved with KpnI; the DNA ends were made blunt with the Klenow fragment of DNA polymerase I and ligated with the polylinker from pSL1190 (Pharmacia), which had been cleaved with EcoRI and HindIII; and the DNA ends were made blunt with the Klenow fragment. This plasmid, pKOS35-151, was cleaved with SpeI and EcoRI and ligated with the 12-kb SpeI-EcoRI fragment from pKOS90-1 to create pKOS35-154.

Plasmid pKOS90-22 was used for recombining the 5' end of the epo gene cluster into the M. xanthus chromosome. First, a portion of the epo genes encoded by module 6 and module 7 was isolated as an 8.8-kb BglII fragment from cosmid pKOS35-70.4 (13) and ligated into the BamHI site of pKOS55-178 to create pKOS90-12. To isolate a fragment upstream of the start of the epo genes, a 9.5-kb NsiI-to-AvrII fragment from cosmid pKOS35-70.8A3 (13) was ligated into the PstI and AvrII sites of pSL1190 to yield pKOS90-13. Next, pKOS35-151 was cleaved with EcoRI and HindIII, the DNA ends were made blunt with the Klenow fragment, and the plasmid was religated. This plasmid, pKOS90-5, was cleaved with MfeI and AvrII and ligated with the 11.5-kb EcoRI-SpeI fragment from pKOS90-12 to construct pKOS90-17. Finally, pKOS90-22 was constructed by cleaving pKOS90-17 with SpeI and ligating it with the 9.5-kb SpeI-AvrII fragment from pKOS90-13.

Construction of an epoK mutant. To construct an epoK mutant, a kanamycin resistance cassette was inserted into the epoK gene. This was done by isolating the 4,879-bp fragment from pKOS35-79.85, which contains epoK, and ligating it into the NotI site of pBluescript SKII(+). This plasmid, pKOS35-83.5, was partially cleaved with ScaI, and the 7.4-kb fragment was ligated with the 1.5-kb EcoRI-BamHI kanamycin resistance gene from pBJ180-2 (B. Julien and D. Kaiser, unpublished), which had the DNA ends made blunt with the Klenow fragment, to yield plasmid pKOS90-55. Finally, the ca. 400-bp RP4 oriT fragment from pBJ183 (Julien and Kaiser, unpublished) was ligated into the XbaI and EcoRI sites to create pKOS90-63. This plasmid was linearized with DraI and electroporated into the M. xanthus strain K111-32.25 to create K111-40.

To create a markerless epoK mutation, pKOS35-83.5 was cleaved with ScaI, and the 2.9- and 4.3-kb fragments were ligated together. This plasmid, pKOS90-101, has an in-frame deletion in epoK. Next, the 3-kb BamHI-NdeI fragment from KG2, which had the DNA ends made blunt with the Klenow fragment and contains the kanamycin resistance and galK genes, was ligated into the DraI site of pKOS90-101 to create pKOS90-105. This plasmid was electroporated into K111-32, and kanamycin-resistant colonies were selected. To replace the wild-type copy of epoK with the deletion, the second recombination event was selected by growth on galactose plates. These galactose-resistant colonies were screened for production of epothilone C and D. This strain is designated K111-72.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Construction of an M. xanthus strain containing the epothilone gene cluster. To reconstruct the epothilone gene cluster in M. xanthus, we chose to introduce the cluster into the chromosome by homologous recombination. This entails placing regions of homology from the epothilone genes into the chromosome of M. xanthus and using these regions as recombination sites for cosmids containing parts of the epo gene cluster. The location on the M. xanthus chromosome chosen for the recombination site was 3' of the dev operon (34). This region encodes no recognizable genes, and insertions in this region are not predicted to disrupt any transcription.

The plasmids used and the strategy for introducing part of the epo genes in M. xanthus are diagramed in Fig. 2 and 3. First, plasmid pKOS35-154 was constructed. This plasmid contains a 7-kb fragment of M. xanthus DNA, 2.8 kb of the dev operon and 4.2 kb downstream of dev, and two regions from the epo gene cluster: a region from module 7 and a region 4.7 kb downstream of epoK. Between the two epo fragments is the kanamycin resistance gene from Tn5 and the E. coli galK gene. Plasmid pKOS35-154 was linearized and electroporated into M. xanthus to produce strain K35-159 (Fig. 3A). Kanamycin-resistant colonies arise from a double recombination event: one recombination with the dev locus and another with the region 3' to dev. This introduces regions from the epo gene cluster that serve as recombination sites for a cosmid containing the downstream half of the epo genes. Next, the cosmid pKOS90-23, which contains epoE, epoF, epoK, and downstream DNA, was electroporated into K35-159 (Fig. 3B). This strain, K35-174.6, results from a single recombination event. To remove the cosmid vector and leave only the region between the two flanking epo regions inserted by plasmid pKOS35-154, a second recombination event was selected by isolating galactose-resistant colonies. The E. coli galK gene renders M. xanthus sensitive to 1% galactose and provides a convenient method for isolating bacteria that have lost the galK gene, which occurs by a second recombination event between the flanking epo region and its homologous DNA on the cosmid. This results in strain K35-175, which contains part of epoE, the complete epoF and epoK genes, and 4.7 kb of DNA downstream (Fig. 3C). The 4.7 kb of DNA downstream of epoK contains several putative open reading frames (arrows in Fig. 3C). None of the open reading frames contain homologies to proteins which would suggest a function. However, the first and last open reading frames encode proteins predicted to harbor membrane spanning regions and so may code for transporter proteins.

View larger version (18K): [in this window] [in a new window]

FIG. 2. Plasmids used for introduction of recombination sites for epothilone genes. Lightly shaded boxes represent regions of DNA from M. xanthus. Dark boxes represent selectable markers or regions of DNA from the epothilone gene cluster. Arrows represent the direction of transcription.

View larger version (33K): [in this window] [in a new window]

FIG. 3. Schematic for introduction of a portion of the epothilone genes into the chromosome of M. xanthus. (A) The introduction of recombination sites for the epothilone genes from pKOS35-154. Arrows indicate direction of transcription. Boxes with curved ends represent partial genes or fragments of DNA from S. cellulosum. (B) Introduction of the cosmid pKOS90-23 into the chromosome. (C) Resulting genetic structure after selecting for the second recombination event to remove duplicated regions and regions with the kanamycin resistance and galK genes. Arrows indicate putative open reading frames and their direction of transcription in the 4.5 kb of S. cellulosum DNA downstream of epoK.

To insert epoA, epoB, epoC, epoD, and the remaining region of epoE, a second round of recombination, similar to the first, was performed. Plasmid pKOS90-22 was linearized and electroporated into K35-175 to construct K111-13.2. Next, cosmid pKOS90-38 was electroporated into K111-13.2 to construct K111-13.22. Finally, to complete the construction of the gene cluster, a galactose-resistant version of K111-13.22 was selected. This final recombinant strain contains the epothilone gene cluster plus 4.7 kb upstream of the translational start of epoA and 4.7 kb downstream of the translational stop of epoK. Eighteen isolates were examined for epothilone production and analyzed by Southern blotting. From this, the two isolates that produced the highest amounts of epothilones were further examined and are referred to as K111-32 isolates 1 and 2.

Although the epothilones are secreted into the medium when produced in S. cellulosum, we were not certain whether a specific transporter was needed to transport the epothilones out of the cell. In constructing the M. xanthus epothilone producer, two open reading frames that appear to encode membrane-spanning proteins were contained within the 65.4 kb of DNA. The two isolates of K111-32 were grown in CMM medium for 60 to 72 h, the period of maximum epothilone accumulation (data not shown), and the levels of epothilone were analyzed in the total culture, which contains the cells and medium together; in the medium; and in the cells alone. The results (Table 1) show that the epothilones are secreted into the medium and only trace amounts are retained in the cells. We currently do not know if the two open reading frames, predicted to encode membrane-spanning proteins, are required for the export of the epothilones.

View this table: [in this window] [in a new window]

TABLE 1. Epothilone production in K111-32

Comparison of the epothilones produced in M. xanthus versus those produced in S. cellulosum shows that the levels of epothilone B are about 100-fold lower in M. xanthus under the growth conditions tested. Interestingly, the ratio of epothilone A to epothilone B produced in M. xanthus is approximately 1:10, in stark contrast to S. cellulosum, where the ratio of epothilone A to epothilone B is roughly 2:1. The difference between epothilone A and epothilone B is the presence of a methyl group at carbon 12. This methyl group is derived from methylmalonyl-CoA and not by C methylation, which indicates that the acyltransferase from module 4 is able to accept either malonyl-CoA or methylmalonyl-CoA (9). Thus, in M. xanthus, there may be a larger pool of methylmalonyl-CoA during epothilone production that increases the production of epothilone B over epothilone A.

Construction of an epoK mutant. Epothilone A and epothilone B are the major constituents of the fermentation of the natural and heterologous hosts. However, epothilone D appears to have the best therapeutic index (5-7, 30). Of the two other candidate drugs currently in clinical trials (22, 26), epothilone B and aza-epothilone B, epothilone D proved superior in reducing tumor size in nude mice containing MX-1 tumor cells. Epothilone B is synthesized from epothilone D by the formation of the epoxide at C-12-C-13, which is added by EpoK, a cytochrome P450 (Fig. 1). This has been demonstrated in vitro by the conversion of epothilone D to epothilone B in the presence of purified EpoK (13). Thus, a strain that contains an epoK mutation would be a valuable strain for production of epothilone D.

Two strains that contain mutations in epoK were constructed. One contains an insertion of the kanamycin gene from Tn5, and the other has an in-frame deletion of epoK that removes 705 bp, or 56% of the gene. Although there are no genes downstream of epoK that are necessary for the synthesis of epothilones, there may be genes important for export, particularly the first open reading frame downstream of epoK that is predicted to contain several transmembrane spanning regions. Therefore, it was important to construct mutations that will not have polar effects. With the insertion, the kanamycin resistance gene is oriented such that its promoter would drive expression of genes downstream of epoK.

Strains harboring mutations in epoK were grown, and the amount of epothilones produced are presented in Fig. 4 A. Isolates of K111-40 contain the insertion of the kanamycin resistance gene (epoK::npt), whereas the isolates of K111-72 contain an in-frame deletion (epoK). The data reveal that the levels of epothilone A from the isolates of K111-32 are similar to the levels of epothilone C from the strains carrying a mutation in epoK and that both types of mutations, the insertion and the in-frame deletion, result in the same levels of production. Interestingly, the levels of epothilone D produced are about fivefold lower than the epoK mutant strains relative to epothilone B produced from K111-32.

View larger version (38K): [in this window] [in a new window]

FIG. 4. Production levels from various strains in the absence (A) or presence (B) of XAD-16.

Because the resin XAD-16 is used in the fermentation of the S. cellulosum strain that produces epothilone, we investigated whether binding of the epothilones to the resin XAD-16 would sequester them from the cells and stabilize the compounds, particularly epothilone D. Figure 4B shows the results of fermentations in the presence XAD-16. The levels of epothilone D produced from the strains harboring the epoK mutation are higher in the presence of XAD and are equivalent to epothilone B levels produced in K111-32. These results suggest that epothilone D is unstable during the fermentation process relative to the other epothilones.

Interestingly, the strain K111-32 produced equal amounts of epothilone B and epothilone D in the presence of XAD-16, even though it contains a fully functional epoK. This is not seen in epothilone production from S. cellulosum. In the presence of XAD-16, epothilone C and epothilone D make up less than 10% of the total amount of epothilones produced in shake flask experiments (B. Julien, unpublished data). This suggests that in S. cellulosum, the majority of the epothilone D is converted to epothilone B before release into the medium, whereas in M. xanthus, epothilone D has an equal probability of being released into the medium as being acted upon by EpoK.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Myxobacteria produce a variety of novel polyketides with novel modes of action, including the epothilones (23, 24). Current understanding of polyketide synthase genes allows them to be engineered to produce novel compounds that may have superior activity relative to the natural ones. However, engineering of genes in strains of S. cellulosum, as well as in most other myxobacteria, would be extremely difficult, due to the lack of genetics and molecular techniques available. Although Streptomyces expression systems have been developed for production of polyketides (14), the yields can be low, and unforeseen side effects of heterologously producing a non-actinomycetes compound, particularly from a gram-negative bacterium, can be problematic, as seen with the epothilones (Tang et al., unpublished data). Thus, the work presented here demonstrates that M. xanthus provides an important alternative host for production of polyketides, especially those from other myxobacteria. Although the levels of epothilones reported here are low, through medium development and using a feeding strategy of Casitone and methyl oleate, current levels of epothilone B are higher than those obtained with the epothilone-producing S. cellulosum strain So ce90 (19). Furthermore, mutants that harbor a mutation in epoK produce 50 to 100 times more epothilone D than does So ce90.

From the work presented here, important information was obtained as to the use of M. xanthus as a heterologous host. First, the strain used has a P-pant transferase that is able to modify both ACP and PCP domains. Second, the strain has a pool of methylmalonyl-CoA during the time of epothilone synthesis. Furthermore, during this time period, there may be more methylmalonyl-CoA than malonyl-CoA, as evidenced by the ratios of epothilone A and epothilone B produced, which is approximately 1:10. Finally, the promoter that drives expression of the epothilone genes in S. cellulosum most likely is the same one that is utilized in M. xanthus. Since no specific regulator proteins have been found associated with any of the several polyketide synthase genes sequenced from S. cellulosum or Stigmatella aurantiaca (13, 20, 27-29), there is likely some global regulator that activates production of secondary metabolites at the onset of stationary phase, and this regulation is similar in many myxobacteria. Further support is provided by the fact that the myxothiazole promoter from S. aurantiaca can drive expression of the epothilone genes in M. xanthus (S. Shah and B. Julien, unpublished data).

Now that epothilone can be produced in a heterologous host tolerant of its production and amenable to genetic manipulation, the stage is set to make new compounds that can only be made by engineering of the genes and to identify those with increased therapeutic value.

 
We thank John Carney for high-performance liquid chromatography and liquid chromatography-mass spectrometry analyses. We thank Dan Santi, David Hopwood, Richard Hutchinson, Leonard Katz, John Carney, Johnathan Kennedy, Yiqing Zhou, and Janice Lau for comments on the manuscript.

 
* Corresponding author. Mailing address: Kosan Biosciences, Inc., 3832 Bay Center Place, Hayward, CA 94545. Phone: (510) 732-8400, ext. 209. Fax: (510) 732-8401. E-mail: julien{at}kosan.com.

Top Abstract Introduction Materials and Methods Results Discussion References

 

1
1. Avery, L., and D. Kaiser. 1983. In situ transposon replacement and isolation of a spontaneous tandem genetic duplication. Mol. Gen. Genet. 191:99-109.[CrossRef][Medline]
2
2. Balog, A., D. Meng, T. Kamenecka, P. Bertinato, D.-S. Su, E. J. Sorensen, and S. J. Danishefsky. 1996. Total synthesis of (-)-epothilone A. Angew. Chem. Int. Ed. Engl. 35:2801-2803.[CrossRef]
3
3. Bollag, D. M., P. A. McQueney, J. Zhu, O. Hensens, L. Koupal, J. Liesch, M. Goetz, E. Lazarides, and C. M. Woods. 1995. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55:2325-2333.[Abstract/Free Full Text]
4
4. Campos, J. M., and D. R. Zusman. 1975. Regulation of development in Myxococcus xanthus: effect of 3':5'-cyclic AMP, ADP, and nutrition. Proc. Natl. Acad. Sci. USA 72:518-522.[Abstract/Free Full Text]
5
5. Chou, T. C., O. A. O'Connor, W. P. Tong, Y. Guan, Z. G. Zhang, S. J. Stachel, C. Lee, and S. J. Danishefsky. 2001. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc. Natl. Acad. Sci. USA 98:8113-8118.[Abstract/Free Full Text]
6
6. Chou, T. C., X. G. Zhang, A. Balog, D. S. Su, D. Meng, K. Savin, J. R. Bertino, and S. J. Danishefsky. 1998. Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc. Natl. Acad. Sci. USA 95:9642-9647.[Abstract/Free Full Text]
7
7. Chou, T. C., X. G. Zhang, C. R. Harris, S. D. Kuduk, A. Balog, K. A. Savin, J. R. Bertino, and S. J. Danishefsky. 1998. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc. Natl. Acad. Sci. USA 95:15798-15802.[Abstract/Free Full Text]
8
8. Gerth, K., N. Bedorf, G. Höfle, H. Irschik, and H. Reichenbach. 1996. Epothilones A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). J. Antibiot. 49:560-563.[Medline]
9
9. Gerth, K., H. Steinmetz, G. Hofle, and H. Reichenbach. 2000. Studies on the biosynthesis of epothilones: the biosynthetic origin of the carbon skeleton. J. Antibiot. 53:1373-1377.[Medline]
10
10. Hopwood, D. A., and D. H. Sherman. 1990. Molecular genetics of polyketides and its comparison to fatty acid biosynthesis. Annu. Rev. Genet. 24:37-66.[CrossRef][Medline]
11
11. Jaoua, S., S. Neff, and T. Schupp. 1992. Transfer of mobilizable plasmids to Sorangium cellulosum and evidence for their integration into the chromosome. Plasmid 28:157-165.[CrossRef][Medline]
12
12. Julien, B., A. D. Kaiser, and A. Garza. 2000. Spatial control of cell differentiation in Myxococcus xanthus. Proc. Natl. Acad. Sci. USA 97:9098-9103.[Abstract/Free Full Text]
13
13. Julien, B., S. Shah, R. Ziermann, R. Goldman, L. Katz, and C. Khosla. 2000. Isolation and characterization of the epothilone biosynthetic gene cluster from Sorangium cellulosum. Gene 249:153-160.[CrossRef][Medline]
14
14. Kao, C. M., L. Katz, and C. Khosla. 1994. Engineered biosynthesis of a complete macrolactone in a heterologous host. Science 265:509-512.[Abstract/Free Full Text]
15
15. Kashefi, K., and P. L. Hartzell. 1995. Genetic suppression and phenotypic masking of a Myxococcus xanthus frzF- defect. Mol. Microbiol. 15:483-494.[CrossRef][Medline]
16
16. Kimura, Y., T. Kojyo, I. Kimura, and M. Sato. 1998. Propionyl-CoA carboxylase of Myxococcus xanthus: catalytic properties and function in developing cells. Arch. Microbiol. 170:179-184.[CrossRef][Medline]
17
17. Kimura, Y., R. Sato, K. Mimura, and M. Sato. 1997. Propionyl coenzyme A carboxylase is required for development of Myxococcus xanthus. J. Bacteriol. 179:7098-7102.[Abstract/Free Full Text]
18
18. Lambalot, R. H., A. M. Gehring, R. S. Flugel, P. Zuber, M. LaCelle, M. A. Marahiel, R. Reid, C. Khosla, and C. T. Walsh. 1996. A new enzyme superfamily: the phosphopantetheinyl transferases. Chem. Biol. 3:923-936.[CrossRef][Medline]
19
19. Lau, J., S. Frykman, R. Regentin, S. Ou, H. Tsuruta, and P. Licari. 2002. Optimizing the heterologous production of epothilone D in Myxococcus xanthus. Biotechnol. Bioeng. 78:280-288.[CrossRef][Medline]
20
20. Ligon, J., S. Hill, J. Beck, R. Zirkle, I. Molnár, J. Zawodny, S. Money, and T. Schupp. 2002. Characterization of the biosynthetic gene cluster for the antifungal polyketide soraphen A from Sorangium cellulosum So ce26. Gene 285:257-267.[CrossRef][Medline]
21
21. LoRusso, P. M., A. J. Wozniak, L. E. Flaherty, A. F. Shields, J. Wright, and D. Lebwohl. 2001. Phase I clinical trial of BMS-247550 (aka epothilone B analog; NSC710428) in adult patients with advanced solid tumors. American Society of Clinical Oncology, San Francisco, Calif.
22
22. Mani, S., H. McDaid, H. Shen, J. A. Sparano, A. Hamilton, C. Runowicz, H. Muggia, A. Fields, B. Damle, S. Letrent, D. Lebwohl, and S. B. Horwitz. 2001. Phase I evaluation of an epothilone B analog (BMS-247550): clinical findings and molecular correlations. American Society of Clinical Oncology, San Francisco, Calif.
23
23. Reichenbach, H., and G. Höfle. 1999. Myxobacteria as producers of secondary metabolites, p. 149-179. In S. Grabley and R. Thieriecke (ed.), Drug discovery. Nature Springer-Verlag, Berlin, Germany.
24
24. Reichenbach, H., and G. Höfle. 1993. Production of bioactive secondary metabolites, p. 347-397. In M. Dworkin and D. Kaiser (ed.), Myxobacteria II. American Society for Microbiology, Washington, D.C.
25
25. Rowinsky, E. K., E. A. Eisenhauer, V. Chaudhry, S. G. Arbuck, and R. C. Donehower. 1993. Clinical toxicities encountered with palitaxel (TAXOL^®). Semin. Oncol. 20:1-15.[Medline]
26
26. Rubin, E. H., L. L. Siu, S. Beers, M. J. Moore, C. Thompson, M. Becker, T. L. Chen, P. Cohen, J. Rothermel, and A. M. Oza. 2001. A phase I and pharmacologic trial of weekly epothilone B in patients with advanced malignancies. American Society of Clinical Oncology, San Francisco, Calif.
27
27. Schupp, T., C. Toupet, B. Cluzel, S. Neff, S. Hill, J. J. Beck, and J. M. Ligon. 1995. A Sorangium cellulosum (myxobacterium) gene cluster for the biosynthesis of the macrolide antibiotic soraphen A: cloning, characterization, and homology to polyketide synthase genes from actinomycetes. J. Bacteriol. 177:3673-3679.[Abstract/Free Full Text]
28
28. Silakowski, B., G. Nordsiek, B. Kunze, H. Blocker, and R. Müller. 2001. Novel features in a combined polyketide synthase/non-ribosomal peptide synthetase: the myxalamid biosynthetic gene cluster of the myxobacterium Stigmatella aurantiaca Sga15(1). Chem. Biol. 8:59-69.[CrossRef][Medline]
29
29. Silakowski, B., H. U. Schairer, H. Ehret, B. Kunze, S. Weinig, G. Nordsiek, P. Brandt, H. Blocker, G. Höfle, S. Beyer, and R. Müller. 1999. New lessons for combinatorial biosynthesis from myxobacteria. The myxothiazol biosynthetic gene cluster of Stigmatella aurantiaca DW4/3-1. J. Biol. Chem. 274:37391-37399.[Abstract/Free Full Text]
30
30. Stachel, S. J., C. B. Lee, M. Spassova, M. D. Chappell, W. G. Bornmann, S. J. Danishefsky, T.-C. Chou, and Y. Guan. 2001. On the interactivity of complex synthesis and tumor pharmacology in the drug discovery process: total synthesis and comparative in vivo evaluations of the 15-aza epothilones. J. Org. Chem. 66:4369-4378.[CrossRef][Medline]
31
31. Su, D.-S., A. Balog, D. Meng, P. Bertinato, S. J. Danishefsky, Y.-H. Zheng, T.-C. Chou, L. He, and S. B. Horwitz. 1997. Structure-activity relationships of the epothilones and the first in vivo comparison with Paclitaxel. Angew. Chem. Int. Ed. Engl. 36:2093-2096.[CrossRef]
32
32. Su, D.-S., D. Meng, P. Bertinato, A. Balog, E. J. Srensen, S. J. Danishefsky, Y.-H. Zheng, T.-C. Chou, L. He, and S. B. Horwitz. 1997. Total synthesis of (-)-epothilone B: an extension of the Suzuki coupling method and insights into structure-activity relationships of the epothilones. Angew. Chem. Int. Ed. Engl. 36:757-759.[CrossRef]
33
33. Tang, L., S. Shah, L. Chung, J. Carney, L. Katz, C. Khosla, and B. Julien. 2000. Cloning and heterologous expression of the epothilone gene cluster. Science 287:640-642.[Abstract/Free Full Text]
34
34. Thöny-Meyer, L., and D. Kaiser. 1993. devRS, an autoregulated and essential genetic locus for fruiting body development in Myxococcus xanthus. J. Bacteriol. 175:7450-7462.[Abstract/Free Full Text]
35
35. Ueki, T., S. Inouye, and M. Inouye. 1996. Positive-negative KG cassettes for construction of multi-gene deletions using a single drug marker. Gene 183:153-157.[CrossRef][Medline]
36
36. Zusman, D. R., D. M. Krotoski, and M. Cumsky. 1978. Chromosome replication in Myxococcus xanthus. J. Bacteriol. 133:122-129.[Abstract/Free Full Text]

---

Antimicrobial Agents and Chemotherapy, September 2002, p. 2772-2778, Vol. 46, No. 9
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.9.2772-2778.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Perlova, O., Fu, J., Kuhlmann, S., Krug, D., Stewart, A. F., Zhang, Y., Muller, R. (2006). Reconstitution of the Myxothiazol Biosynthetic Gene Cluster by Red/ET Recombination and Heterologous Expression in Myxococcus xanthus. Appl. Environ. Microbiol. 72: 7485-7494 [Abstract] [Full Text]  
• Zirkle, R., Ligon, J. M., Molnar, I. (2004). Heterologous production of the antifungal polyketide antibiotic soraphen A of Sorangium cellulosum So ce26 in Streptomyces lividans. Microbiology 150: 2761-2774 [Abstract] [Full Text]  
• Lei, L., Waterman, M. R., Fulco, A. J., Kelly, S. L., Lamb, D. C. (2004). Availability of specific reductases controls the temporal activity of the cytochrome P450 complement of Streptomyces coelicolor A3(2). Proc. Natl. Acad. Sci. USA 101: 494-499 [Abstract] [Full Text]  
• Julien, B. (2003). Characterization of the Integrase Gene and Attachment Site for the Myxococcus xanthus Bacteriophage Mx9. J. Bacteriol. 185: 6325-6330 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Julien, B. Articles by Shah, S. Search for Related Content PubMed PubMed Citation Articles by Julien, B. Articles by Shah, S.